Obesity

Rocuronium dose in obesity surgery – Sugammadex and Ideal Body Weight in Bariatric Surgery

Talk with your doctor and family members or friends about deciding to join a study.

All on who met the inclusion criteria were approached to participate in the study. As the obese patients have a different drug distribution and body composition, we investigated the safety and efficacy of Sugammadex according to the ideal body weight IBW. Table 1 Calculation, advantages, and disadvantages of weight scalars. Neuromuscular transmission was monitored according to good clinical practice recommendations, as follows. Perioperative management of obese patients.

  • At the end of surgery, Sugammadex was administrated at recovery.

  • Information from the National Library of Medicine Choosing to participate in a study is an important personal decision.

  • During laparoscopic bariatric surgery, an infusion rate of 0. Dosing based on total body weight TBW may cause overdose and prolonged duration of action.

  • Search ADS.

Publication types

Find the highest correlation between the 8 factors total body weight, corrected body weight, ideal body weight, rocuronium dose in obesity surgery mass, body mass index, skeletal muscle mass, body fat and the amount of rocuronium administered to deep neuromuscular blockade in bariatric surgery. National Library of Medicine U. Determinants on Rocuronium Dose for Deep Block in Bariatric Surgery The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

  • Abstract Objectives: To compare onset time, duration of action, and tracheal intubation conditions in obese patients when the intubation dose of rocuronium was based on corrected body weight CBW versus lean body weight LBW for rapid sequence induction. Materials and Methods.

  • Conclusions: In obese patients undergoing global childhood obesity strategies banding or gastric bypass, rocuronium dosed according to IBW provided a shorter duration of action without a significantly prolonged onset time or compromised conditions for tracheal intubation. For general information, Learn About Clinical Studies.

  • The primary endpoint in this study was to evaluate the recovery times to of 0. Its effects terminate within 5—10 min after stopping the infusion.

  • The patients received rocuronium 0. Please refer to this study by its ClinicalTrials.

  • See Contacts and Locations.

Detailed Description:. Department of Health and Obesith Services. National Institutes of Health U. Bariatric Surgery. The rocuronium dose in obesity surgery end point was duration of action, defined as time to reappearance of the fourth twitch in train-of-four. Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.

Please refer to this study by its ClinicalTrials. Conclusions: Rocuronuim obese patients undergoing gastric banding or gastric bypass, rocuronium dosed according to IBW provided a shorter duration of action without a significantly prolonged onset time or compromised conditions for tracheal intubation. Read our disclaimer for details. January 14, Key Record Dates.

MeSH terms

MO subjects given an induction dose based on LBW rocuroniun similar amounts of propofol and similar times to loss of consciousness compared with lean subjects given propofol based on TBW. Claudius, L. Benedict, A. After a single bolus dose, thiopental is rapidly distributed from the plasma to the peripheral tissues. For Permissions, please email: journals.

Primary Outcome Measures : the highest correlation coefficient [ Time Frame: preoperative 1 days to postoperative 1 days ] the relationship of rocuronium rocuronium dose in obesity surgery deep neuromuscular blockade in sugrery surgery and 8 factors corrected body weight, ideal body weight, lean body weight, fat-free mass, body mass index, skeletal muscle mass, body fat. Estimated Primary Completion Date :. In this study, we compared onset time, conditions for tracheal intubation, and duration of action in obese patients when the intubation dose of rocuronium was based on three different weight corrections. National Library of Medicine U. Search for terms x.

Rocuronium dose in obesity surgery primary endpoint in this study was to evaluate the recovery times to of 0. Awareness of the boesity of the commonly used anaesthetic agents including induction agents, opioids, inhalation agents and neuromuscular blockers is necessary for safe and effective care of morbidly obese patients. Their use has been advocated in patients with compromised renal function. Eleveld et al.

MeSH terms

Search for terms x. Listing a study does not mean it has been evaluated by the U. Abstract Background: Pharmacokinetic studies in obese patients suggest that dosing of rocuronium should be based on ideal body weight IBW.

Eligibility Criteria. The patients received rocuronium 0. Relationship between the muscle relaxation effect and body muscle mass measured using bioelectrical impedance analysis: A nonrandomized controlled trial. Layout table for location rocuronium dose in obesity surgery Contact: Jiwon Han, Dr hanjiwon snubh. Drug: deep neuromuscular blockade in bariatric surgery obese patients who underwent bariatric surgery. Secondary Outcome Measures : onset time of rocuronium [ Time Frame: preoperative 1 days to postoperative 1 days ] time from injection of rocuronium 0. Before the surgery, total body weight, corrected body weight, ideal body weight, fat-free mass, body mass index were measured by height and weight and skeletal muscle mass and body fat were measured by Bioelectrical impedance analysis InbodyH20B.

READ TOO: Obesity And Poverty In America

For MO patients in particular, changes obesity surgery body composition and changes in cardiac output and regional blood rocuronium dose must doss considered. Patients with obstructive sleep apnea syndrome were also excluded. Issue Section:. Its use might not be appropriate in subjects with hypotension, heart block, or severe cardiomyopathy. Previous dose-finding studies were restricted to reversal of profound deep or moderate rocuronium neuromuscular block [ 18 — 21 ].

After the reappearance of T1, if the neuromuscular blockade was insufficient for surgery, supplementary rocuronium 10 mg was given. View at: Google Scholar D. Citing articles via Web Of Science Abernethy and D.

What We Already Know about This Topic

Abstract Background: Pharmacokinetic studies in obese patients suggest that dosing of rocuronium should be based on ideal body weight IBW. Neuromuscular function was monitored with train-of-four nerve stimulation and acceleromyography. January 14, Key Record Dates.

Abstract Background: Pharmacokinetic studies in obese patients suggest that rocuronium dose in obesity surgery of rocuronium should be based on ideal body weight IBW. J Int Med Res. Neuromuscular function was monitored with train-of-four nerve stimulation and acceleromyography. This may, however, result in a prolonged onset time or compromised conditions for tracheal intubation. Secondary Outcome Measures : onset time of rocuronium [ Time Frame: preoperative 1 days to postoperative 1 days ] time from injection of rocuronium 0. Drug: deep neuromuscular blockade in bariatric surgery obese patients who underwent bariatric surgery. Department of Health and Human Services.

Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information. Warning You have reached the maximum number rocuronium dose in obesity surgery saved studies Before rocuronium dose in obesity surgery surgery, total body weight, corrected body weight, ideal body weight, fat-free mass, body mass index were measured by height and weight and skeletal muscle mass and body fat were measured by Bioelectrical impedance analysis InbodyH20B. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. J Int Med Res. Save this study. This may, however, result in a prolonged onset time or compromised conditions for tracheal intubation.

Dosing scalars

We estimated a 10 min SD and a difference of 10 min in time to reappearance of T1 based on a previous study. Since the rate of obesity is expected to increase further in the future, 2 anesthesiologists are being more frequently confronted with obese patients in their daily work. The efficacy of sugammadex administration was reflected by the time required to obtain a TOFR of 0. Compound A has been shown to cause nephrotoxicity in animal studies, but this has not been observed in humans.

  • When used for propofol TCI, this model can result in higher infusion rates during maintenance of anaesthesia. Br J Clin Pharmacol ; —

  • Listing a study does not mean it has been evaluated by the U.

  • Inhalation agents. The line of regression of slope 0.

  • Study Type :.

  • Although MO subjects have increased extracellular fluid volume compared with normal weight subjects, it is not entirely understood how this affects rocuronium dosing. Greenblatt, and M.

The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients. The use of shorter acting neuromuscular blockers such as rocuronium, vecuronium, or cisatracurium is preferred rocuronium dose in obesity surgery the MO population. Likewise, the percentage of patients requiring a second dose of sugammadex tended to be larger in the deep blockade group Prediction of clearance, volume of distribution and half-life by allometric scaling and by use of plasma concentrations predicted from pharmacokinetic constants: a comparative study. Faster wash-out and recovery for desflurane vs sevoflurane in morbidly obese patients when no premedication is used. Bom, F. E-mail: hlemmens stanford.

This study explored the sugammadex dose adjusted according to train-of-four ratio TOFR. The durations of intubation and maintenance doses of rocuronium were similar in both groups. Anaesthetizing MO individuals requires careful considerations regarding changes in the PK and PD properties of numerous drugs used in anaesthesia. Relationship between propofol induction dose and body weight in lean control subjects and MO subjects. Driessen, M. Br J Anaesth.

Substances

Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. Curley GF. Lean-scaled weight: a proposed weight scalar to calculate drug doses for obese patients.

Nonetheless, reversal took more than 4 min in three of our patients with moderate blocks even when an additional dose of sugammadex was administered. Drobnik et al. Kendall, M. However, there are no data available describing the relationship between cardiac output and LBW in subjects with obesity-related cardiomyopathy, which might invalidate dose administration based upon LBW in such individuals. Marzano, and A. Select Format Select format.

Curley GF. E-mail: moc. Randomized comparison of isoflurane and sevoflurane for laparoscopic gastric banding in morbidly obese patients. Wash-in and wash-out curves of sevoflurane and isoflurane in morbidly obese patients. The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients.

  • Sign In or Create an Account. Onset and duration of action of rocuronium--from tracheal intubation, through intense block to complete recovery.

  • Determinants on Rocuronium Dose for Deep Block in Bariatric Surgery The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

  • Effects of obesity on pharmacokinetics implications for drug therapy.

  • Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil.

  • Search for terms x.

Estimated Enrollment :. FDA Resources. National Library of Medicine U. Background: Pharmacokinetic studies in obese patients suggest that dosing of rocuronium should be based on ideal body weight IBW. Bariatric Surgery.

J Int Med Res. Outcome Measures. Detailed Description:. More Information. Last Update Posted : January 14, Drug: deep neuromuscular blockade in bariatric surgery. Search for terms x.

Obessity Outcome Measures : the highest correlation coefficient [ Time Rocuronium dose in obesity surgery preoperative 1 days to postoperative 1 rocuronium dose in obesity surgery ] the relationship of rocuronium for deep neuromuscular blockade in bariatric surgery and 8 factors corrected body weight, ideal body weight, lean body weight, fat-free mass, body mass index, skeletal muscle mass, body fat. The patients received rocuronium 0. National Library of Medicine U. Study record managers: refer to the Data Element Definitions if submitting registration or results information. For general information, Learn About Clinical Studies.

  • Although MO subjects have increased extracellular fluid volume compared with normal weight subjects, it is not entirely understood how this affects rocuronium dosing.

  • Abstract Background: Pharmacokinetic studies in obese patients suggest that dosing of rocuronium should be based on ideal body weight IBW. Read our disclaimer for details.

  • In small doses, Sugammadex may form complexes only with molecules of rocuronium in the central compartment and cannot sustain the redistribution from peripheral to central compartments. Please review our privacy policy.

  • Balsiger, M.

  • IngrandeJ. Sign In or Create an Account.

The increased lipophilicity of isoflurane coupled with the increased fat mass in MO subjects would increase peripheral tissue uptake. View large Download slide. Eleveld et al. Application of physiologic models to predict the influence of changes in body composition and blood flows on the pharmacokinetics of fentanyl and alfentanil in patients. This Site. View Large.

  • Two patients in the deep blockade group and four in the moderate blockade group required reoperation; four patients one in the deep blockade group and three in the moderate blockade group required readmission to the surgical intensive care unit. The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients.

  • To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below.

  • A Letter to Editor for this article has been published. Sugammadex effectiveness was reflected by the time required to obtain a TOFr of 0.

  • Estimated Study Completion Date :. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision.

  • The increased cardiac output in MO individuals lowers plasma fentanyl concentrations during the early distribution phase.

Skip Nav Destination Article Navigation. The median times surgwry to TOFR of 0. No signs of residual neuromuscular block were observed in any patient during the clinical assessment in the recovery room. Kendall, M. Lomangino, B. Succinylcholine is a depolarizing neuromuscular blocker with a rapid onset and short duration of action.

Banoub and V. Faster wash-out rocuronium dose in obesity surgery recovery rocurnium desflurane vs sevoflurane rocuronium dose in obesity surgery morbidly obese patients when no premedication is used. Figure 1. Earlier studies on dosing rocuronium in obese patients were performed with 0. Duration of action, defined as the time from the start of the rocuronium injection to achievement of one response to TOF stimulation T1 was recorded. No significant differences were observed between the groups in intubation conditions or onset time seconds median, interquartile range [IQR].

Table 4. Desflurane has been advocated for use in MO patients because it is the least lipophilic fose least-soluble volatile anaesthetic available, and theoretically has limited distribution into adipose tissue. Critical Care. However, overdoses, such as would result from using RBW in morbidly obese patients in the standard calculations, would be costly and ineffective in a high number of patients given the aforementioned ceiling effect.

Clin Chest Med. At a level of statistical significance of 0. Br J Anaesth ; rocurnoium Abstract Objectives: To compare onset time, duration of action, and tracheal intubation conditions in obese patients when the intubation dose of rocuronium was based on corrected body weight CBW versus lean body weight LBW for rapid sequence induction. Sign In. Norrild, P.

Relationship between the muscle relaxation effect and strategies muscle mass measured using bioelectrical impedance analysis: A nonrandomized controlled trial. Drug: deep global childhood obesity blockade in bariatric surgery. Please refer to this study by its ClinicalTrials. Secondary Outcome Measures : onset time of rocuronium [ Time Frame: preoperative 1 days to postoperative 1 days ] time from injection of rocuronium 0. J Int Med Res.

Substances

National Institutes of Health U. Determinants on Rocuronium Dose for Deep Block in Bariatric Surgery The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Epub Feb 5.

Information from the National Library of Medicine To learn more about rocuronium dose study, you or your doctor may contact the study research staff obesity surgery the contact information provided by the sponsor. January 14, Key Record Dates. Conclusions: In obese patients undergoing gastric banding or gastric bypass, rocuronium dosed according to IBW provided a shorter duration of action without a significantly prolonged onset time or compromised conditions for tracheal intubation. Before the surgery, total body weight, corrected body weight, ideal body weight, fat-free mass, body mass index were measured by height and weight and skeletal muscle mass and body fat were measured by Bioelectrical impedance analysis InbodyH20B.

Anesthesia was maintained obesity sevoflurane with an end-tidal concentration of 1. The introduction of bariatric surgery has been a considerable breakthrough in the surgery of these patients [ 7 rocuronium dose. Administering drugs eose on TBW can result in an overdose, while administration based on IBW can result in a subtherapeutic dose. Therefore, although supported by references, the following is an opinion-based review of dosing scalars used in MO patients and the effects of obesity on the clinical pharmacology of commonly used anaesthetic agents. The Lean Body Mass LBM represents muscle relaxants biophase in its totality, that is, the junctional pre- and postsynaptic membrane, the intersynaptic fluid, interstitial space volume, and its vessels. Pharmacokinetic mass of fentanyl for postoperative analgesia in lean and obese patients.

Relationship statistics propofol induction dose and body weight in lean control subjects and MO childhood obesity 2013. Sign In or Rocuronim an Account. Table 2. External link. Oxford Academic. Written information about the study was given to all patients and was explained orally; patients were enrolled if they gave signed consent to use of their data. Among our morbidly obese patients in deep neuromuscular blockade, on the other hand, recovery occurred only after 5 min in six outliers even though these patients had received a second dose of sugammadex.

Anesthesiology Research and Practice

Drug: deep neuromuscular blockade in bariatric surgery obese patients who underwent bariatric surgery. J Int Med Res. More Information. Find out the deciding factor total body weight, corrected body weight, ideal body weight, fat-free mass, body mass index, skeletal muscle mass, body fat of neuromuscular blocker dose for deep neuromuscular blockade in bariatric surgery.

Find the highest correlation between the 8 factors rocuronium dose body weight, corrected body weight, ideal body weight, fat-free mass, body mass index, skeletal muscle rocuronium dose in obesity surgery, body fat and the amount of rocuronium obesity surgery to deep neuromuscular blockade in bariatric surgery. More Information. In this study, we compared onset time, conditions for tracheal intubation, and duration of action in obese patients when the intubation dose of rocuronium was based on three different weight corrections. Listing a study does not mean it has been evaluated by the U. Secondary Outcome Measures : onset time of rocuronium [ Time Frame: preoperative 1 days to postoperative 1 days ] time from injection of rocuronium 0. Relationship between the muscle relaxation effect and body muscle mass measured using bioelectrical impedance analysis: A nonrandomized controlled trial. Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.

READ TOO: Karangan Obesity Format Spm Fizik

National Institutes of Health U. In this study, we compared onset time, conditions for tracheal intubation, and duration of action in obese patients when the intubation dose of rocuronium was based on three different weight corrections. Last Update Posted : January 14, Read our disclaimer for details. Listing a study does not mean it has been evaluated by the U.

The primary end point was duration of action, defined as time to reappearance of the fourth twitch in train-of-four. Neuromuscular function was monitored with train-of-four nerve stimulation childhood obesity 2013 statistics acceleromyography. Talk with your obesiry and family members or friends about deciding to join a study. Conclusions: In obese patients undergoing gastric banding or gastric bypass, rocuronium dosed according to IBW provided a shorter duration of action without a significantly prolonged onset time or compromised conditions for tracheal intubation. The patients received rocuronium 0. Propofol was administered as a bolus of mg and an infusion at 5 mg x kg -1 x h -1 and remifentanil was administered at 1. Contacts and Locations.

Estimated Study Completion Obesity surgery :. Conclusions: In obese patients undergoing gastric banding or gastric bypass, rocuronium dosed according to IBW provided a shorter duration of action rocuronium dose a significantly prolonged onset time or compromised conditions for tracheal intubation. Outcome Measures. Read our disclaimer for details. Secondary Outcome Measures : onset time of rocuronium [ Time Frame: preoperative 1 days to postoperative 1 days ] time from injection of rocuronium 0. Drug: deep neuromuscular blockade in bariatric surgery. More Information.

What This Article Tells Us That Is New

Please review our privacy policy. IBW group. Can J Anesth ; —7.

  • A probability approach to detect a mechanomyographic train-of-four ratio of 0. Fentanyl or dexmedetomidine combined with desflurane for bariatric surgery.

  • Estimated Study Completion Date :.

  • The use of target-controlled infusion TCI delivery systems has improved the accuracy of anaesthetic drug delivery during induction and maintenance of anaesthesia.

  • Find out the deciding factor total body weight, corrected body weight, ideal body weight, fat-free mass, body mass index, skeletal muscle mass, body fat of neuromuscular blocker dose for deep neuromuscular blockade in bariatric surgery. Estimated Study Completion Date :.

  • Federal Government. January 14, Key Record Dates.

Outcome Measures. Estimated Study Completion Date :. Search for terms x. More Information. In this study, we compared onset time, conditions for tracheal intubation, and duration of action in obese patients when the intubation dose of rocuronium was based on three different weight corrections.

READ TOO: Obese Doxie Dog Pictures

Drug: deep neuromuscular blockade in bariatric surgery obese patients who underwent bariatric surgery. This rocurknium, however, result in a prolonged onset time or compromised conditions for tracheal intubation. Bariatric Surgery. Estimated Study Completion Date :. J Int Med Res. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Contacts and Locations.

References 1. Cisatracurium and atracurium are benzylisoquinolones with an average duration of effect of 30—40 min after a single intubating rocuronium dose in obesity surgery of 0. Volume rocuronium dose in obesity surgery, Issue 1. Pharmacokinetics of fentanyl administered by computer-controlled infusion pump. The blockade was deep at the end of surgery in 43 and moderate in A loading dose of dexmedetomidine 0. Once surgery ended, neuromuscular monitoring was recorded and sugammadex was administered to all patients, as described below, after discontinuing the hypnotic agent.

Find the highest correlation between the 8 factors total suryery weight, corrected rocuronium dose in obesity surgery weight, ideal body weight, fat-free mass, body mass index, skeletal muscle mass, body fat and the amount of rocuronium administered to deep neuromuscular blockade in bariatric surgery. Estimated Primary Completion Date :. Find out the deciding factor total body weight, corrected body weight, ideal body weight, fat-free mass, body mass index, skeletal muscle mass, body fat of neuromuscular blocker dose for deep neuromuscular blockade in bariatric surgery.

  • Drobnik, H.

  • Abstract Background: Pharmacokinetic studies in obese patients suggest that dosing of rocuronium should be based on ideal body weight IBW.

  • Bom, F.

  • Neuromuscular blockade should be fully reversed before tracheal extubation.

Drug: deep neuromuscular blockade in bariatric surgery. Contacts and Locations. National Institutes of Health U. Eligibility Criteria.

The obese patients have differences in body composition, rocuronium dose in obesity surgery distribution, and metabolism. Authors have no conflict of interest, and the work rocuronium dose in obesity surgery not supported or funded by any drug company. Therefore, although supported by references, the following is an opinion-based review of dosing scalars used in MO patients and the effects of obesity on the clinical pharmacology of commonly used anaesthetic agents. We did not randomize our patients to moderate or deep blockade during recovery; therefore, even though our two study groups were comparable, lack of randomization remains a formal limitation of our study. Michael P.

Contacts and Locations. Bariatric Surgery. Study record managers: refer to the Data Element Definitions if submitting registration or results information.

Even after a TOFR rocuronium dose in obesity surgery 0. Close mobile search navigation Article Navigation. Among obesitj morbidly obese patients in deep neuromuscular blockade, on the other hand, recovery occurred only after 5 min in six outliers even though these patients had received a second dose of sugammadex. Sign In. Adamus et al 19 showed that the onset time was shorter and the clinical duration of rocuronium was increased in female patients, and claimed that females were more sensitive than males to a single bolus dose of rocuronium. Search ADS.

Kendall, M. Lean body weight is the optimal scalar for most i. Search Abstracts. Pharmacokinetic studies show that weakly lipophilic drugs such as rocuronium should be dosed on ideal body weight IBWrather than real body weight RBW [ 8 ].

Other variables recorded were patient characteristics including comorbidity and American Society of Anesthesiologists risk rocuronium dose in obesity surgerysurgical and perioperative variables including intra- and postoperative eventsand hospital stay. Patients with obstructive sleep apnea syndrome were also excluded. LBW is significantly correlated to cardiac output, 14 which is an important determinant in the early distribution kinetics of drugs.

Detailed Description:. Drug: deep neuromuscular blockade in bariatric surgery obese patients who underwent bariatric surgery. National Institutes of Health U. Last Update Posted : January 14,

To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. Listing a study does not mean it has been evaluated by the U. Study Type :. Federal Government.

  • In addition, its short duration of action allows earlier resumption of spontaneous ventilation should difficulty in securing the airway be encountered.

  • To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below.

  • The normal distribution of continuous variables was dowe with a Kolmogorov—Smirnov test; a nonparametric Mann—Whitney U test was used to compare continuous variables and a chi-square test was used to compare discontinuous variables. An infusion based on LBW results in similar plasma concentrations as normal weight subjects were given an infusion based on TBW.

  • January 14, Key Record Dates.

Secondary Outcome Measures : rocufonium time of rocuronium dose [ Time Frame: preoperative 1 days obesity surgery postoperative 1 days ] time from injection of rocuronium 0. For general information, Learn About Clinical Studies. The patients received rocuronium 0. Read our disclaimer for details. The primary end point was duration of action, defined as time to reappearance of the fourth twitch in train-of-four. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Contacts and Locations.

However, there are no data rocuronium dose describing the relationship between obesity surgery output and LBW in rocurobium with obesity-related cardiomyopathy, which might invalidate dose administration based upon LBW in such individuals. The median dose of rocuronium given was 0. Drobnik et al. Prediction of clearance, volume of distribution and half-life by allometric scaling and by use of plasma concentrations predicted from pharmacokinetic constants: a comparative study. Dexmedetomidine infusion during laparoscopic bariatric surgery: the effect on recovery outcome variables. This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.

SPSS software version Obese subjects require significantly more pancuronium than lean subjects to maintain constant twitch depression. The use of allometric scaling to derive PK parameters is not without limitations. Bom, F. Learn More.

The difference in results between our study and that of Gaszynski et al 21 using Surrgery might be 2013 statistics patients were taller in that childhood obesity compared to our present obesity surgery, and rocuronium dose patients of the same height received the same dose. Download all slides. Address correspondence and reprint request to: Dr. View at: Publisher Site Google Scholar. Leykin et al 9 studied a rocuronium dose of 0. All patients were placed in semisitting position to make ventilation and airway management easier. Obese subjects require significantly more pancuronium than lean subjects to maintain constant twitch depression.

Comparison of decreases in ventilation caused by enflurane and fentanyl during anaesthesia. Allometric scaling. Leykin et al 9 studied a rocuronium dose of 0. As a novel finding, rocuronium 1. Body mass index is associated with increased creatinine clearance by a mechanism independent of body fat distribution. Conflict of interest. Dosing recommendations are generally based on TBW.

Collections